Découverte et amélioration des cas d’utilisation du cannabis

As acceptance of Cannabis has grown over the past few years, so has our understanding of the medication/drug.  Despite this, researchers believe that many beneficial but untapped effects of the medication have yet to be discovered.  This has resulted in continued research, which recently saw scientists create various CBN analogs poised to help sufferers of various neurological disorders, in addition to discovering new approaches to eliminating certain unwanted side effects of cannabis use.

Deux pas en avant pour le cannabis

In recent weeks, we have seen not one but two studies released touting new insights into how Cannabis functions and the role it can play in protecting the human body.  The following is a brief look at these developments.

Réduction de l’anxiété

When it comes to Cannabis, one of the most common reasons for consumption is to treat anxiety.  Interestingly, the well-known active ingredient, THC, may actually worsen anxiety if too much is consumed.  Une équipe de recherche de Johns Hopkins Medicine a récemment découvert that a solution may also be contained within Cannabis in the form of a terpene known as d-limonene.

The team found that this abundant terpene “significantly reduced overall ratings of feeling “anxious/nervous” and “paranoid” compared with rating the effect of THC alone.”  The findings were the result of a double-blind test and are being touted as a step toward mitigating the “…risks of THC when used in medicine.”

Notably, Cannabis contains over 100 different terpenes, with their effects on THC and CBD largely unknown.  Moving forward, the study of these compounds will continue, hopefully providing further insights for safe consumption, like the ones involving d-limonène and its ability to keep anxiety in check.

Protection des cellules cérébrales

For decades, Cannabis use has been, largely anecdotally, linked with killing brain cells.  While this may be true in certain instances, it has yet to be proven.  Interestingly, a recent study actually shows that Cannabis may hold the key to protecting brain cells from various ailments, which include,

• traumatismes crâniens
• maladie d’Alzheimer
• maladie de Parkinson

More specifically, des scientifiques du Salk Institute ont publié une étude supporting this through experimenting with certain cannabinoids like cannabinol (CBN).  The team found that CBN boasts ‘neuroprotective’ properties by preventing the degradation of mitochondria – a process directly responsible for the death of brain cells.

Promisingly, the team also created a quartet of its own CBN analogs, which boasted even better neuroprotective properties, giving hope that they may one day be a viable treatment for sufferers of either traumatic brain injuries or neurodisorders.

Acceptation accrue = Compréhension accrue

As mentioned, our understanding of Cannabis and its potential as a medication has greatly increased over the past few years alongside its broader acceptance among the public.  This acceptance continues to grow as Cannabis has been legal for recreational use in Canada in 2018.

In the United States, acceptance has also grown – albeit not to the extent seen north of the border.  While it is legal in various states, it remains illegal on a Federal level.  Notably, this has become a talking point as of late among certain politicians and presidential candidates like RFK Jr., who are looking to follow Canada’s steps regarding its legality.  Regardless of whether this happens, the fact remains that increased acceptance is leading to an increased understanding of the drug/medication, resulting in promising findings.

Spécialistes du cannabis

While the fervor surrounding the Cannabis has waxed and waned over the past few years, a few companies have managed to establish themselves as important and resilient industry fixtures.  The following are examples of such companies that have done just that.  For a more thorough look at industry participants, make sure to visiter notre analyse des meilleures actions de ce marché en pleine croissance.

*Les chiffres fournis ci-dessous étaient exacts au moment de la rédaction et sont susceptibles de changer. Tout investisseur potentiel doit vérifier les métriques*

1. Canopy Growth Corporation

(CGC )

Canopy Growth Corporation, headquartered in Smiths Falls, Ontario, is a premier global cannabis company that has broadened its offerings to include a variety of cannabis and hemp products.  Facing the common industry challenges of regulatory changes and market volatility, Canopy has strategically streamlined operations through workforce reductions and facility closures, alongside refocusing on its most lucrative markets.  Despite these challenges, the company has maintained a robust brand presence and continued to invest in innovation, showcasing its resilience and adaptability.

Canopy Growth Corporation, dont le siège se trouve à Smiths Falls, en Ontario, est une entreprise mondiale de premier plan dans le secteur du cannabis qui a élargi son offre pour inclure une variété de produits à base de cannabis et de chanvre. Confrontée aux défis courants de l’industrie tels que les changements réglementaires et la volatilité du marché, Canopy a rationalisé ses opérations de manière stratégique en réduisant ses effectifs et en fermant des installations, tout en se recentrant sur ses marchés les plus rentables. Malgré ces défis, l’entreprise a maintenu une présence de marque solide et continue d’investir dans l’innovation, démontrant ainsi sa résilience et son adaptabilité.

En tant qu’investissement, Canopy Growth est attrayante grâce à son portefeuille de produits diversifié, ses partenariats stratégiques comme celui avec Constellation Brands, et son empreinte mondiale en expansion, notamment sur le marché américain du CBD. Ces facteurs, combinés à la croissance anticipée du marché mondial du cannabis, positionnent Canopy Growth comme une option convaincante pour les investisseurs cherchant une exposition à l’industrie du cannabis, offrant un potentiel à mesure que le marché continue de mûrir et de se stabiliser.

Au moment de la rédaction, CGC était classé par la majorité des analystes comme un ‘Conserver’

2. Tilray Brands

(TLRY )

Tilray Brands, Inc., another global pioneer in cannabis research, cultivation, production, and distribution, has emerged as a significant player in the cannabis industry.  Following its merger with Aphria in 2021, the company has solidified its position, leveraging enhanced production capabilities and an extensive distribution network to meet medical and recreational cannabis demand.  Despite facing the volatility typical of the burgeoning cannabis market, including price fluctuations and competitive pressures, Tilray has continued to expand its product lines and explore new market opportunities, focusing on strategic acquisitions and partnerships that enhance its market reach and operational efficiencies.

Tilray Brands, Inc., un autre pionnier mondial de la recherche, de la culture, de la production et de la distribution de cannabis, est devenu un acteur majeur de l’industrie du cannabis. Suite à sa fusion avec Aphria en 2021, l’entreprise a consolidé sa position, tirant parti de capacités de production renforcées et d’un vaste réseau de distribution pour répondre à la demande de cannabis médical et récréatif. Malgré la volatilité typique du marché émergent du cannabis, incluant les fluctuations de prix et la pression concurrentielle, Tilray a continué d’élargir ses gammes de produits et d’explorer de nouvelles opportunités de marché, en se concentrant sur des acquisitions stratégiques et des partenariats qui améliorent sa portée et son efficacité opérationnelle.

Pour les investisseurs intéressés par le secteur du cannabis, Tilray Brands représente un cas convaincant grâce à sa stratégie de croissance agressive et à sa gestion proactive des défis du marché. Les efforts de l’entreprise pour construire une activité diversifiée, des applications pharmaceutiques du cannabis aux biens de consommation emballés, ainsi que son expansion continue sur les marchés internationaux, la positionnent favorablement pour une croissance à long terme. Ces initiatives, combinées à sa présence établie sur les marchés clés, font de Tilray une opportunité d’investissement notable alors que l’industrie mondiale du cannabis continue d’évoluer et de s’étendre.

Au moment de la rédaction, TLRY était classé par la majorité des analystes comme un ‘Acheter’